Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 8/20 | 0.52 |
| ▸ | ALAD | P13716 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2182135 | 0.81 | MAPT (0.52) | DAOCES2CES1KDM4EALDH1A1 | |
| SCHEMBL9974183 | 0.80 | CTPS1 (0.40) | DAOKDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL6455719 | 0.77 | ALAD (0.65) | DAOALADHDAC6TTR | |
| SCHEMBL361988 | 0.72 | ALDH1A1 (0.40) | HDAC3HDAC4HDAC1HDAC6KDM4E | |
| SCHEMBL23092955 | 0.72 | ALDH1A1 (0.37) | DAOALDH1A1 | |
| SCHEMBL1934481 | 0.71 | DAO (0.41) | DAOALAD | |
| SCHEMBL166310 | 0.70 | — | — | |
| SCHEMBL166311 | 0.70 | — | — | |
| SCHEMBL425130 | 0.70 | — | — | |
| SCHEMBL71474 | 0.70 | DAO (0.58) | DAOALADHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612399-B2 | Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-28 | — | — | US | disclosed |
| WO-2025231161-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-11-06 | — | — | WO | disclosed |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | AI BIO DISCOVERY LLC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12275721-B2 | Indazole carboxamides as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-11-21 | — | — | US | disclosed |
| CN-115087651-B | Indazole carboxamides as kinase inhibitors | 百时美施贵宝公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4305022-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2024-01-17 | — | — | EP | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-30 | — | — | US | disclosed |
| WO-2011153315-A1 | MODIFIED C-3 BETULINIC ACID DERIVATIVES AS HIV MATURATION INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-08 | — | — | WO | disclosed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2265616-A1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2010120370-A2 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-2114950-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009100282-A1 | FURO-AND THIENO[3,2-C] PYRIDINES | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | DAO 492/4885ALAD 350/4885HDAC3 2107/4885 |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | RET, MET, ERBB2 | DAO 2606/4885ALAD 4593/4885HDAC3 1324/4885 |
| US-12275721-B2 | Indazole carboxamides as kinase inhibitors | RIPK3, RIPK1, RIPK2 | DAO 4351/4885ALAD 4578/4885HDAC3 385/4885 |
| US-12612399-B2 | Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof | SNCA, CBR1, CBR3 | DAO 720/4885ALAD 3450/4885HDAC3 246/4885 |
| US-20240383852-A1 | ANTI-VIRAL COMPOUNDS | PREP, DNPEP, PLP2 | DAO 741/4885ALAD 1806/4885HDAC3 525/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | DAO 1718/4885ALAD 3631/4885HDAC3 467/4885 |
| US-20230382904-A1 | SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PARK7 | DAO 756/4885ALAD 1638/4885HDAC3 564/4885 |
| US-20250332181-A1 | ANTIBIOTIC METHODS AND COMPOSITIONS | CMBL, EBPL, BPGM | DAO 18/4885ALAD 96/4885HDAC3 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.